Didier Smadja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Didier Smadja has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Nicolas Chausson
Department of Neurology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
5 shared publications Nicolas Chausson
Institut de Psychiatrie et Neurosciences de Paris, Inserm U1266, Paris, France
4 shared publications- Gaultier Marnat
Department of Neuroradiology, Bordeaux University Hospital, Bordeaux, France
3 shared publications - Guillaume Turc
Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (N.C., J.B., W.B.H., D.S., G.T.).
3 shared publications Manvel Aghasaryan
Sud Francilien Hospital, FRANCE
3 shared publications- Constance Flamand-Roze
Neurologie, CHU Bicêtre, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
2 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3224-3232
Early Recanalization After Tenecteplase or Alteplase in Distal and Medium Vessel Occlusion Strokes: An Observational Cohort Study
BACKGROUND: Intravenous thrombolysis remains the standard treatment for distal and medium vessel occlusion (DMVO) strokes. However, unlike large vessel occlusions, whether tenecteplase achieves higher early successful recanalization rates than alteplase in DMVO strokes remains uncertain. METHODS: This single-center observational cohort study included consecutive patients with magnetic resonance imaging (MRI)-confirmed DMVO stroke treated at Centre Hospitalier Sud-Francilien, France, according to an institutional thrombolysis protocol specifying alteplase (0.9 mg/kg, 2016–2018) or tenecteplase (0.25 mg/kg, 2018–2023), with follow-up MRI 1 to 2 hours after intravenous thrombolysis. Patients intended for endovascular thrombectomy or without diagnostic-quality follow-up MRI were excluded. Recanalization was blindly assessed using a modified Arterial Occlusion Lesion scale designed for MRI and DMVO. Early successful recanalization was defined as ≥50% recanalization on early follow-up MRI (grade ≥2b), and substantial early infarct growth, assessed using a semiautomatic segmentation technique, was defined as a ≥0.5 mL and ≥20% increase in lesion volume. Propensity-score weighting accounted for baseline imbalances, including age, sex, vascular risk factors, baseline National Institutes of Health Stroke Scale score, occlusion site, and time period (2020–2023 versus 2016–2019). RESULTS: Of the 319 included patients, 159 were treated with tenecteplase and 160 with alteplase. Median baseline National Institutes of Health Stroke Scale was 3 (1–7) in the tenecteplase group versus 4 (1–7.5) in the alteplase group, while M2 occlusions accounted for 54.1% versus 43.8% of cases. Early successful recanalization, assessed at a median postintravenous thrombolysis time of 80 (70–94) minutes, occurred in 72 (45.3%) and 53 (33.1%) patients treated with tenecteplase and alteplase, respectively (propensity-score weighting–odds ratio, 1.59 [95% CI, 1.15–2.20]; P =0.005). Substantial early infarct growth was observed in 42 (26.8%) and 64 (40.5%) patients, respectively (propensity-score weighting–odds ratio, 0.49 [95% CI, 0.35–0.69]; P <0.0001). CONCLUSIONS: Compared with alteplase, tenecteplase-treated patients with DMVO had higher early successful recanalization and a lower risk of substantial early infarct growth, supporting its preferential use in this setting. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05635786.
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3224-3232
Early Recanalization After Tenecteplase or Alteplase in Distal and Medium Vessel Occlusion Strokes: An Observational Cohort Study
BACKGROUND: Intravenous thrombolysis remains the standard treatment for distal and medium vessel occlusion (DMVO) strokes. However, unlike large vessel occlusions, whether tenecteplase achieves higher early successful recanalization rates than alteplase in DMVO strokes remains uncertain. METHODS: This single-center observational cohort study included consecutive patients with magnetic resonance imaging (MRI)-confirmed DMVO stroke treated at Centre Hospitalier Sud-Francilien, France, according to an institutional thrombolysis protocol specifying alteplase (0.9 mg/kg, 2016–2018) or tenecteplase (0.25 mg/kg, 2018–2023), with follow-up MRI 1 to 2 hours after intravenous thrombolysis. Patients intended for endovascular thrombectomy or without diagnostic-quality follow-up MRI were excluded. Recanalization was blindly assessed using a modified Arterial Occlusion Lesion scale designed for MRI and DMVO. Early successful recanalization was defined as ≥50% recanalization on early follow-up MRI (grade ≥2b), and substantial early infarct growth, assessed using a semiautomatic segmentation technique, was defined as a ≥0.5 mL and ≥20% increase in lesion volume. Propensity-score weighting accounted for baseline imbalances, including age, sex, vascular risk factors, baseline National Institutes of Health Stroke Scale score, occlusion site, and time period (2020–2023 versus 2016–2019). RESULTS: Of the 319 included patients, 159 were treated with tenecteplase and 160 with alteplase. Median baseline National Institutes of Health Stroke Scale was 3 (1–7) in the tenecteplase group versus 4 (1–7.5) in the alteplase group, while M2 occlusions accounted for 54.1% versus 43.8% of cases. Early successful recanalization, assessed at a median postintravenous thrombolysis time of 80 (70–94) minutes, occurred in 72 (45.3%) and 53 (33.1%) patients treated with tenecteplase and alteplase, respectively (propensity-score weighting–odds ratio, 1.59 [95% CI, 1.15–2.20]; P =0.005). Substantial early infarct growth was observed in 42 (26.8%) and 64 (40.5%) patients, respectively (propensity-score weighting–odds ratio, 0.49 [95% CI, 0.35–0.69]; P <0.0001). CONCLUSIONS: Compared with alteplase, tenecteplase-treated patients with DMVO had higher early successful recanalization and a lower risk of substantial early infarct growth, supporting its preferential use in this setting. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05635786.
- 1 December 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 10 (4) , 1346-1353
Sex differences in outcomes and time to treatment in stroke patients treated with tenecteplase
Introduction: A better understanding of sex-related differences remains key to improve stroke care for women. We aimed to assess the differences of prognosis, symptomatic intracranial hemorrhage (sICH) rates and process times between men and women suffering from ischemic stroke. Patients and methods: We performed a sex-based retrospective analysis of the French Tenecteplase Treatment in Stroke multicentric registry from 2015 to 2021. We assessed sex differences in terms of 3-month good neurological outcome (defined as modified Rankin score ⩽ 2 or back to its pre-stroke value), occurrence of sICH and process times with multivariable logistic regression analyses. Results: 1339 consecutive patients (684 women, 655 men) received tenecteplase between 2015 and 2021, among whom 873 underwent thrombectomy. Both groups differed in terms of demographic characteristics, etiology, and unclear onset. In multivariable logistic regression analyses, women and men did not differ in terms of 3-month good neurological outcome (aOR = 0.85 [0.63–1.13]). Women were less likely to have a sICH after tenecteplase (aOR = 0.35 [0.18–0.69]) and more likely to have a stroke of unknown onset (aOR 1.44 [1.07–1.95]), but workflow metrics did not differ once stroke code was triggered. Discussion and conclusion: In our study, we did not find a significant difference between women and men in terms of 3-month good outcome. However, our study size may hinder its detection. Interestingly, we observed that women had a lower rate of sICH after tenecteplase. Women’s workflow metrics were similar to men’s, except for a higher rate of stroke with an unknown onset.
- 1 December 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 10 (4) , 1346-1353
Sex differences in outcomes and time to treatment in stroke patients treated with tenecteplase
Introduction: A better understanding of sex-related differences remains key to improve stroke care for women. We aimed to assess the differences of prognosis, symptomatic intracranial hemorrhage (sICH) rates and process times between men and women suffering from ischemic stroke. Patients and methods: We performed a sex-based retrospective analysis of the French Tenecteplase Treatment in Stroke multicentric registry from 2015 to 2021. We assessed sex differences in terms of 3-month good neurological outcome (defined as modified Rankin score ⩽ 2 or back to its pre-stroke value), occurrence of sICH and process times with multivariable logistic regression analyses. Results: 1339 consecutive patients (684 women, 655 men) received tenecteplase between 2015 and 2021, among whom 873 underwent thrombectomy. Both groups differed in terms of demographic characteristics, etiology, and unclear onset. In multivariable logistic regression analyses, women and men did not differ in terms of 3-month good neurological outcome (aOR = 0.85 [0.63–1.13]). Women were less likely to have a sICH after tenecteplase (aOR = 0.35 [0.18–0.69]) and more likely to have a stroke of unknown onset (aOR 1.44 [1.07–1.95]), but workflow metrics did not differ once stroke code was triggered. Discussion and conclusion: In our study, we did not find a significant difference between women and men in terms of 3-month good outcome. However, our study size may hinder its detection. Interestingly, we observed that women had a lower rate of sICH after tenecteplase. Women’s workflow metrics were similar to men’s, except for a higher rate of stroke with an unknown onset.
- Open Access
Elaboration and validation of R-LAST (Right Language Screening Test), a rapid and reliable screening tool to detect cognitive communication disorders in acute right hemisphere stroke
Background The role of the right hemisphere in language use and interpretive abilities has become clearer through studies describing sequelae in patients with right hemisphere stroke (RHS). Between 50% and 78% of stroke survivors with RHS experience communication disorders, a condition recently termed “apragmatism” by a group of experts. Apragmatism can negatively impact individuals’ personal lives and overall quality of life. Objective To develop and validate a bedside cognitive and communication screening tool for features of apragmatism in prospective patients with right stroke, called the Right Language Screening Test (R-LAST), which is simple, rapid, and suitable for emergency settings. Patients and methods R-LAST consists of seven subtests and twelve items. We report its internal and external validity and inter-rater reliability. We validated the scale by prospectively administering it to 300 patients admitted to two stroke units with confirmed right stroke, as well as to 94 stabilized patients with and without cognitive-communication disorders, using the MEC B as a reference. Results Internal validity demonstrated no redundancy with a Pearson coefficient less than 0.8. The internal consistency of the 12 items was questionable, indicated by a Cronbach’s alpha of 0.62. External validation against MEC B revealed a sensitivity of 0.84 and a specificity of 0.82. Inter-rater agreement was nearly perfect (ICC 0.993). The average time needed to complete R-LAST was 3 minutes and 52 seconds. Conclusion R-LAST could enable rapid and reliable detection of apragmatism in the acute phase of stroke, which could lead to timely referrals to speech-language therapists and ensure timely rehabilitation. This comprehensively validated cognitive-communication disorders rating scale is simple and rapid, making it a useful tool for bedside evaluation of acute stroke patients in routine clinical practice. Clinical Trial Registration Unique Identifier: NCT03622606 URL: https://clinicaltrials.gov/study/NCT03622606?term=R-LAST&rank=1
Open AccessElaboration and validation of R-LAST (Right Language Screening Test), a rapid and reliable screening tool to detect cognitive communication disorders in acute right hemisphere stroke
Background The role of the right hemisphere in language use and interpretive abilities has become clearer through studies describing sequelae in patients with right hemisphere stroke (RHS). Between 50% and 78% of stroke survivors with RHS experience communication disorders, a condition recently termed “apragmatism” by a group of experts. Apragmatism can negatively impact individuals’ personal lives and overall quality of life. Objective To develop and validate a bedside cognitive and communication screening tool for features of apragmatism in prospective patients with right stroke, called the Right Language Screening Test (R-LAST), which is simple, rapid, and suitable for emergency settings. Patients and methods R-LAST consists of seven subtests and twelve items. We report its internal and external validity and inter-rater reliability. We validated the scale by prospectively administering it to 300 patients admitted to two stroke units with confirmed right stroke, as well as to 94 stabilized patients with and without cognitive-communication disorders, using the MEC B as a reference. Results Internal validity demonstrated no redundancy with a Pearson coefficient less than 0.8. The internal consistency of the 12 items was questionable, indicated by a Cronbach’s alpha of 0.62. External validation against MEC B revealed a sensitivity of 0.84 and a specificity of 0.82. Inter-rater agreement was nearly perfect (ICC 0.993). The average time needed to complete R-LAST was 3 minutes and 52 seconds. Conclusion R-LAST could enable rapid and reliable detection of apragmatism in the acute phase of stroke, which could lead to timely referrals to speech-language therapists and ensure timely rehabilitation. This comprehensively validated cognitive-communication disorders rating scale is simple and rapid, making it a useful tool for bedside evaluation of acute stroke patients in routine clinical practice. Clinical Trial Registration Unique Identifier: NCT03622606 URL: https://clinicaltrials.gov/study/NCT03622606?term=R-LAST&rank=1
- Open Access
Efficacy of Simultaneous Infusion of Tirofiban with Intravenous Thrombolysis in Patients with Acute Anterior Choroidal or Paramedian Pontine Infarction: TITACIPPI Study
Background and Purpose: Intravenous thrombolysis combined with tirofiban (IVT plus tirofiban) has been reported to be more effective than IVT alone in preventing early neurological deterioration (END) and improving 3-month functional outcomes in patients with ischemic stroke. This study aimed to assess the radiological efficacy and safety of simultaneous (or within 60 minutes) IVT plus tirofiban versus IVT alone specifically in patients with anterior choroidal infarction (ACI) or paramedian pontine infarction (PPI), two subtypes with a high risk of END. Methods: We conducted a single-center, retrospective study including consecutive patients aged ≥18 years treated during two distinct periods: one with standard IVT alone and one with IVT plus tirofiban. The primary endpoint was ≥20% reduction in lesion volume on 24-hour diffusion-weighted imaging (DWI). Secondary endpoints included early clinical improvement at 24 hours and 7 days (or discharge), functional independence (modified Rankin Scale (mRS) scores ≤2 and ≤1) at 3 months, and END. Safety outcomes included symptomatic intracranial hemorrhage (sICH) and major systemic bleeding (MSB). A subgroup analysis compared clinical outcomes in patients with « lesion reversal » versus patients with no « lesion reversal ». Results: A total of 58 patients were analyzed (30 IVT plus tirofiban; 28 IVT alone). Lesion reversal ≥20% was more frequently observed in the IVT plus tirofiban group (adjusted odds ratio, 8.58; 95% CI, 2.09–35.28; p=0.001). No significant differences were found between groups for END or 3-month functional outcomes (mRS ≤2 or ≤1). One non-fatal MSB occurred in the IVT alone group. No cases of sICH were observed in either group. Overall lesion reversal was significantly associated with better early and late outcomes, and with IVT plus tirofiban treatment. Discussion and Conclusions: This study suggests that IVT plus tirofiban improves radiological outcomes and may be a promising therapeutic option in patients with ACI/PPI, without increasing the risk of bleeding compared to IVT alone. KEY MESSAGE: What is already known on this topic: Branch atheromatous disease related ischemic strokes (BADRIS) carry a substantial risk of long-term disability because early neurological deterioration (END) is frequent even after intravenous thrombolysis (IVT). However, the role of IVT in preventing END in patients with BADRIS is not well established. What this study adds: This single-center retrospective study provides real-world evidence that IVT plus tirofiban is associated with a lesion reversal ≥20% on 24-hour diffusion-weighted imaging (DWI) compared to IVT alone. The study also provides evidence that lesion reversal is associated with better early and late outcomes, and with IVT plus tirofiban treatment. How this study might affect research, practice or policy: These findings support the use of IVT plus tirofiban in patients with BADRIS. This combination promotes lesion reversal, thereby improving functional outcomes and reducing the risk of END. Larger prospective multicenter randomized trials are needed to confirm these findings and to determine whether this strategy provides a functional benefit at 3 months.
Open AccessEfficacy of Simultaneous Infusion of Tirofiban with Intravenous Thrombolysis in Patients with Acute Anterior Choroidal or Paramedian Pontine Infarction: TITACIPPI Study
Background and Purpose: Intravenous thrombolysis combined with tirofiban (IVT plus tirofiban) has been reported to be more effective than IVT alone in preventing early neurological deterioration (END) and improving 3-month functional outcomes in patients with ischemic stroke. This study aimed to assess the radiological efficacy and safety of simultaneous (or within 60 minutes) IVT plus tirofiban versus IVT alone specifically in patients with anterior choroidal infarction (ACI) or paramedian pontine infarction (PPI), two subtypes with a high risk of END. Methods: We conducted a single-center, retrospective study including consecutive patients aged ≥18 years treated during two distinct periods: one with standard IVT alone and one with IVT plus tirofiban. The primary endpoint was ≥20% reduction in lesion volume on 24-hour diffusion-weighted imaging (DWI). Secondary endpoints included early clinical improvement at 24 hours and 7 days (or discharge), functional independence (modified Rankin Scale (mRS) scores ≤2 and ≤1) at 3 months, and END. Safety outcomes included symptomatic intracranial hemorrhage (sICH) and major systemic bleeding (MSB). A subgroup analysis compared clinical outcomes in patients with « lesion reversal » versus patients with no « lesion reversal ». Results: A total of 58 patients were analyzed (30 IVT plus tirofiban; 28 IVT alone). Lesion reversal ≥20% was more frequently observed in the IVT plus tirofiban group (adjusted odds ratio, 8.58; 95% CI, 2.09–35.28; p=0.001). No significant differences were found between groups for END or 3-month functional outcomes (mRS ≤2 or ≤1). One non-fatal MSB occurred in the IVT alone group. No cases of sICH were observed in either group. Overall lesion reversal was significantly associated with better early and late outcomes, and with IVT plus tirofiban treatment. Discussion and Conclusions: This study suggests that IVT plus tirofiban improves radiological outcomes and may be a promising therapeutic option in patients with ACI/PPI, without increasing the risk of bleeding compared to IVT alone. KEY MESSAGE: What is already known on this topic: Branch atheromatous disease related ischemic strokes (BADRIS) carry a substantial risk of long-term disability because early neurological deterioration (END) is frequent even after intravenous thrombolysis (IVT). However, the role of IVT in preventing END in patients with BADRIS is not well established. What this study adds: This single-center retrospective study provides real-world evidence that IVT plus tirofiban is associated with a lesion reversal ≥20% on 24-hour diffusion-weighted imaging (DWI) compared to IVT alone. The study also provides evidence that lesion reversal is associated with better early and late outcomes, and with IVT plus tirofiban treatment. How this study might affect research, practice or policy: These findings support the use of IVT plus tirofiban in patients with BADRIS. This combination promotes lesion reversal, thereby improving functional outcomes and reducing the risk of END. Larger prospective multicenter randomized trials are needed to confirm these findings and to determine whether this strategy provides a functional benefit at 3 months.
- 1 August 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (8) , 2091-2100
Delay in Carotid Web Diagnosis Remains Common and Associated With an Increased Risk of Stroke Recurrence
BACKGROUND: Carotid web is a rare and likely underrecognized cause of ischemic stroke, particularly in young patients. Given the high risk of recurrence, diagnostic delays may have serious consequences. This study aimed to assess the incidence and impact of delayed carotid web diagnosis after a first ischemic event. METHODS: We conducted a retrospective analysis using data from the French ongoing multicenter prospective CAROWEB (Carotid Web registry). We included patients with a first-ever ischemic stroke or transient ischemic attack in the anterior circulation, attributed to an ipsilateral carotid web with no other identifiable cause, between September 2013 and April 2023. Patients with missing data on the date of the first ischemic event or carotid web diagnosis, or with prior stroke history, were excluded. Participants were categorized into early diagnosis (≤30 days) and delayed diagnosis (>30 days) groups. Factors associated with diagnostic delay were investigated through univariable and multivariable analyses. Stroke recurrence was evaluated using Kaplan-Meier survival analysis. RESULTS: Of 280 patients in the registry, 225 met the inclusion criteria. A delayed diagnosis occurred in 57 patients (25.3%). Independent predictors of diagnostic delay included lower initial National Institutes of Health Stroke Scale score (odds ratio, 0.92; P =0.002), stroke occurring before 2019 (odds ratio, 0.19; P P P =0.014). CONCLUSIONS: Delayed carotid web diagnosis remains common, especially in minor strokes, in the absence of early computed tomography angiography, and in events before 2019. Such delays are associated with a significantly increased risk of stroke recurrence, highlighting the need for early vascular imaging in ischemic stroke evaluation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04431609.
- 1 August 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (8) , 2091-2100
Delay in Carotid Web Diagnosis Remains Common and Associated With an Increased Risk of Stroke Recurrence
BACKGROUND: Carotid web is a rare and likely underrecognized cause of ischemic stroke, particularly in young patients. Given the high risk of recurrence, diagnostic delays may have serious consequences. This study aimed to assess the incidence and impact of delayed carotid web diagnosis after a first ischemic event. METHODS: We conducted a retrospective analysis using data from the French ongoing multicenter prospective CAROWEB (Carotid Web registry). We included patients with a first-ever ischemic stroke or transient ischemic attack in the anterior circulation, attributed to an ipsilateral carotid web with no other identifiable cause, between September 2013 and April 2023. Patients with missing data on the date of the first ischemic event or carotid web diagnosis, or with prior stroke history, were excluded. Participants were categorized into early diagnosis (≤30 days) and delayed diagnosis (>30 days) groups. Factors associated with diagnostic delay were investigated through univariable and multivariable analyses. Stroke recurrence was evaluated using Kaplan-Meier survival analysis. RESULTS: Of 280 patients in the registry, 225 met the inclusion criteria. A delayed diagnosis occurred in 57 patients (25.3%). Independent predictors of diagnostic delay included lower initial National Institutes of Health Stroke Scale score (odds ratio, 0.92; P =0.002), stroke occurring before 2019 (odds ratio, 0.19; P P P =0.014). CONCLUSIONS: Delayed carotid web diagnosis remains common, especially in minor strokes, in the absence of early computed tomography angiography, and in events before 2019. Such delays are associated with a significantly increased risk of stroke recurrence, highlighting the need for early vascular imaging in ischemic stroke evaluation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04431609.
- 15 April 2025
- Published by Elsevier in Vascular Diseases
- Vol. 50 (1) , 11
Web carotidiens : aspects cliniques
- 15 April 2025
- Published by Elsevier in Vascular Diseases
- Vol. 50 (1) , 11
Web carotidiens : aspects cliniques
- 15 April 2025
- Published by Elsevier in Vascular Diseases
- Vol. 50 (1) , 13
Des réponses avec CAROWEB
- 1 December 2024
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 9 (4) , 943-951
Second-dose intravenous thrombolysis with tenecteplase in alteplase-resistant medium-vessel-occlusion strokes: A retrospective and comparative study
Introduction: In intracranial medium-vessel occlusions (MeVOs), intravenous thrombolysis (IVT) shows inconsistent effectiveness and endovascular interventions remains unproven. We evaluated a new therapeutic strategy based on a second IVT using tenecteplase for MeVOs without early recanalization post-alteplase. Patients and methods: This retrospective, comparative study included consecutively low bleeding risk MeVO patients treated with alteplase 0.9 mg/kg at two stroke centers. One center used a conventional single-IVT approach; the other applied a dual-IVT strategy, incorporating a 1-h post-alteplase MRI and additional tenecteplase, 0.25 mg/kg, if occlusion persisted. Primary outcomes were 24-h successful recanalization for efficacy and symptomatic intracranial hemorrhage (sICH) for safety. Secondary outcomes included 3-month excellent outcomes (modified Rankin Scale score of 0–1). Comparisons were conducted in the overall cohort and a propensity score-matched subgroup. Results: Among 146 patients in the dual-IVT group, 103 failed to achieve recanalization at 1 h and of these 96 met all eligible criteria and received additional tenecteplase. Successful recanalization at 24 h was higher in the 146 dual-IVT cohort patients than in the 148 single-IVT cohort patients (84% vs 61%, p < 0.0001), with similar sICH rate (3 vs 2, p = 0.68). Dual-IVT strategy was an independent predictor of 24-h successful recanalization (OR, 2.7 [95% CI, 1.52–4.88]; p < 0.001). Dual-IVT cohort patients achieved higher rates of excellent outcome (69% vs 44%, p < 0.0001). Propensity score matching analyses supported all these associations. Conclusion: In this retrospective study, a dual-IVT strategy in selected MeVO patients was associated with higher odds of 24-h recanalization, with no safety concerns. However, potential center-level confounding and biases seriously limit these findings’ interpretation. Trial Registration: ClinicalTrials.gov Identifier: NCT05809921
- 1 December 2024
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 9 (4) , 943-951
Second-dose intravenous thrombolysis with tenecteplase in alteplase-resistant medium-vessel-occlusion strokes: A retrospective and comparative study
Introduction: In intracranial medium-vessel occlusions (MeVOs), intravenous thrombolysis (IVT) shows inconsistent effectiveness and endovascular interventions remains unproven. We evaluated a new therapeutic strategy based on a second IVT using tenecteplase for MeVOs without early recanalization post-alteplase. Patients and methods: This retrospective, comparative study included consecutively low bleeding risk MeVO patients treated with alteplase 0.9 mg/kg at two stroke centers. One center used a conventional single-IVT approach; the other applied a dual-IVT strategy, incorporating a 1-h post-alteplase MRI and additional tenecteplase, 0.25 mg/kg, if occlusion persisted. Primary outcomes were 24-h successful recanalization for efficacy and symptomatic intracranial hemorrhage (sICH) for safety. Secondary outcomes included 3-month excellent outcomes (modified Rankin Scale score of 0–1). Comparisons were conducted in the overall cohort and a propensity score-matched subgroup. Results: Among 146 patients in the dual-IVT group, 103 failed to achieve recanalization at 1 h and of these 96 met all eligible criteria and received additional tenecteplase. Successful recanalization at 24 h was higher in the 146 dual-IVT cohort patients than in the 148 single-IVT cohort patients (84% vs 61%, p < 0.0001), with similar sICH rate (3 vs 2, p = 0.68). Dual-IVT strategy was an independent predictor of 24-h successful recanalization (OR, 2.7 [95% CI, 1.52–4.88]; p < 0.001). Dual-IVT cohort patients achieved higher rates of excellent outcome (69% vs 44%, p < 0.0001). Propensity score matching analyses supported all these associations. Conclusion: In this retrospective study, a dual-IVT strategy in selected MeVO patients was associated with higher odds of 24-h recanalization, with no safety concerns. However, potential center-level confounding and biases seriously limit these findings’ interpretation. Trial Registration: ClinicalTrials.gov Identifier: NCT05809921
- 1 December 2024
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 9 (4) , 918-926
Incidence and predictors of intracranial hemorrhage after intravenous thrombolysis with tenecteplase
Background: Despite its increasing use, there are limited data on the risk of intracranial hemorrhage (ICH) after intravenous thrombolysis with tenecteplase in the setting of acute ischemic stroke. Our aim was to investigate the incidence and predictors of ICH after tenecteplase administration. Methods: We reviewed data from the prospective ongoing multicenter TETRIS (Tenecteplase Treatment in Ischemic Stroke) registry. Patients with available day-1 imaging were included in this study. Clinical, imaging and biological variables were collected. Follow-up imaging performed 24 h after IVT was locally reviewed by senior neuroradiologists and neurologists. The incidence of parenchymal hematoma (PH) and any ICH were investigated. Potential predictors of PH and any ICH were assessed in multivariable logistic regressions. Subgroup analyses focusing on patients intended for endovascular treatment were performed. Results: PH and any ICH occurred in 126/1321 (incidence rate: 9.5%, 95% CI 8.1–11.2) and 521/1321 (39.4%, 95% CI 36.8–42.1) patients, respectively. Symptomatic ICH was observed in 77/1321 (5.8%; 95% CI 4.7–7.2). PH occurrence was significantly associated with poorer functional outcomes (p < 0.0001) and death (p < 0.0001) after 3 months. Older age (aOR = 1.03; 95% CI 1.01–1.05), male gender (aOR = 2.07; 95% CI 1.28–3.36), a history of hypertension (aOR = 2.08; 95% CI 1.19–3.62), a higher baseline NIHSS (aOR = 1.07; 95% CI 1.03–1.10) and higher admission blood glucose level (aOR = 1.12; 95% CI 1.05–1.19) were independently associated with PH occurrence. Similar associations were observed in the subgroup of patients intended for endovascular treatment. Conclusion: We quantified the incidence of ICH after IVT with tenecteplase in a real-life prospective registry and determined independent predictors of ICH. These findings allow to identify patients at high risk of ICH.
- 1 December 2024
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 9 (4) , 918-926
Incidence and predictors of intracranial hemorrhage after intravenous thrombolysis with tenecteplase
Background: Despite its increasing use, there are limited data on the risk of intracranial hemorrhage (ICH) after intravenous thrombolysis with tenecteplase in the setting of acute ischemic stroke. Our aim was to investigate the incidence and predictors of ICH after tenecteplase administration. Methods: We reviewed data from the prospective ongoing multicenter TETRIS (Tenecteplase Treatment in Ischemic Stroke) registry. Patients with available day-1 imaging were included in this study. Clinical, imaging and biological variables were collected. Follow-up imaging performed 24 h after IVT was locally reviewed by senior neuroradiologists and neurologists. The incidence of parenchymal hematoma (PH) and any ICH were investigated. Potential predictors of PH and any ICH were assessed in multivariable logistic regressions. Subgroup analyses focusing on patients intended for endovascular treatment were performed. Results: PH and any ICH occurred in 126/1321 (incidence rate: 9.5%, 95% CI 8.1–11.2) and 521/1321 (39.4%, 95% CI 36.8–42.1) patients, respectively. Symptomatic ICH was observed in 77/1321 (5.8%; 95% CI 4.7–7.2). PH occurrence was significantly associated with poorer functional outcomes (p < 0.0001) and death (p < 0.0001) after 3 months. Older age (aOR = 1.03; 95% CI 1.01–1.05), male gender (aOR = 2.07; 95% CI 1.28–3.36), a history of hypertension (aOR = 2.08; 95% CI 1.19–3.62), a higher baseline NIHSS (aOR = 1.07; 95% CI 1.03–1.10) and higher admission blood glucose level (aOR = 1.12; 95% CI 1.05–1.19) were independently associated with PH occurrence. Similar associations were observed in the subgroup of patients intended for endovascular treatment. Conclusion: We quantified the incidence of ICH after IVT with tenecteplase in a real-life prospective registry and determined independent predictors of ICH. These findings allow to identify patients at high risk of ICH.
- Open Access
- 9 May 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (5) , 619
Neurorehabilitation through Hippotherapy on Neurofunctional Sequels of Stroke: Effect on Patients’ Functional Independence, Sensorimotor/Cognitive Capacities and Quality of Life, and the Quality of Life of Their Caregivers—A Study Protocol
Background: Stroke is a high burden illness and the second leading cause of worldwide disability with generally poor recovery rates. Robust benefits of hippotherapy, a novel neurorehabilitation approach, in functional recovery following various severe neurological disabling conditions has been shown. In the present study, we will analyze the effect of a hippotherapy program on the outcome of post-stroke patients in the first year post-stroke. Method: A randomized controlled clinical trial on the effectiveness of hippotherapy (4 weeks/18 weeks hippotherapy/conventional neurorehabilitation) versus conventional neurorehabilitation alone (22 weeks) will be conducted over 48 weeks. In the treated group, one-hour daily hippotherapy sessions will be exclusively conducted during the hippotherapy’s cycles, alternated with periods of conventional neurorehabilitation. A test battery will measure both the functional and psychological outcomes. The primary endpoint will be the patient’s functional independence. The secondary endpoints will measure the sensorimotor function, autonomy, and quality of life, as well as the caregivers’ quality of life. Results and conclusion: Individual brain connectome, life history and personality construct influence the brain’s functional connectivity and are central to developing optimal tailored neurorehabilitation strategies. According to our current practice, hippotherapy allows the enhancement of substantial neuroplastic changes in the injured brain with significant neurological recovery. The protocol aims to confirm those issues. Trial registration in ClinicalTrials.gov NCT04759326 accessed on 19 February 2021.
- 9 May 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (5) , 619
Open AccessNeurorehabilitation through Hippotherapy on Neurofunctional Sequels of Stroke: Effect on Patients’ Functional Independence, Sensorimotor/Cognitive Capacities and Quality of Life, and the Quality of Life of Their Caregivers—A Study Protocol
Background: Stroke is a high burden illness and the second leading cause of worldwide disability with generally poor recovery rates. Robust benefits of hippotherapy, a novel neurorehabilitation approach, in functional recovery following various severe neurological disabling conditions has been shown. In the present study, we will analyze the effect of a hippotherapy program on the outcome of post-stroke patients in the first year post-stroke. Method: A randomized controlled clinical trial on the effectiveness of hippotherapy (4 weeks/18 weeks hippotherapy/conventional neurorehabilitation) versus conventional neurorehabilitation alone (22 weeks) will be conducted over 48 weeks. In the treated group, one-hour daily hippotherapy sessions will be exclusively conducted during the hippotherapy’s cycles, alternated with periods of conventional neurorehabilitation. A test battery will measure both the functional and psychological outcomes. The primary endpoint will be the patient’s functional independence. The secondary endpoints will measure the sensorimotor function, autonomy, and quality of life, as well as the caregivers’ quality of life. Results and conclusion: Individual brain connectome, life history and personality construct influence the brain’s functional connectivity and are central to developing optimal tailored neurorehabilitation strategies. According to our current practice, hippotherapy allows the enhancement of substantial neuroplastic changes in the injured brain with significant neurological recovery. The protocol aims to confirm those issues. Trial registration in ClinicalTrials.gov NCT04759326 accessed on 19 February 2021.